Karyopharm Therapeutics (NASDAQ:KPTI) Trading Down 4.1%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were down 4.1% during trading on Tuesday . The stock traded as low as $7.24 and last traded at $7.24. Approximately 3,947 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 1,949,599 shares. The stock had previously closed at $7.55.

KPTI has been the topic of several research reports. Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $30.00 to $17.00 and set an “outperform” rating on the stock in a report on Friday, August 6th. HC Wainwright reduced their price objective on Karyopharm Therapeutics from $49.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, August 6th. SVB Leerink downgraded Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating and set a $6.00 price objective on the stock. in a report on Friday, August 6th. Zacks Investment Research raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 9th. Finally, Royal Bank of Canada downgraded Karyopharm Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $17.00 to $8.00 in a report on Thursday, August 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Karyopharm Therapeutics currently has an average rating of “Hold” and a consensus target price of $14.83.

The stock has a 50 day moving average price of $6.51 and a two-hundred day moving average price of $7.60. The company has a market cap of $581.71 million, a price-to-earnings ratio of -2.79 and a beta of 0.09.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, November 3rd. The company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.01). Karyopharm Therapeutics had a negative net margin of 173.81% and a negative return on equity of 7,204.16%. During the same period in the prior year, the firm posted ($0.73) EPS. Research analysts predict that Karyopharm Therapeutics Inc. will post -2.88 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Royal Bank of Canada lifted its stake in Karyopharm Therapeutics by 107.5% in the 1st quarter. Royal Bank of Canada now owns 12,344 shares of the company’s stock valued at $130,000 after acquiring an additional 6,394 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Karyopharm Therapeutics in the 1st quarter valued at approximately $315,000. Tudor Investment Corp Et Al bought a new stake in Karyopharm Therapeutics in the 1st quarter valued at approximately $877,000. Morgan Stanley lifted its stake in Karyopharm Therapeutics by 128.6% in the 1st quarter. Morgan Stanley now owns 1,698,473 shares of the company’s stock valued at $17,868,000 after acquiring an additional 955,560 shares in the last quarter. Finally, Tarbox Family Office Inc. bought a new stake in Karyopharm Therapeutics in the 2nd quarter valued at approximately $31,000. Hedge funds and other institutional investors own 79.92% of the company’s stock.

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Further Reading: What is the Difference Between Common Shares and Convertible Shares?

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.